Literature DB >> 25640907

Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes.

Anna Hiu Yi Wong1, Thirugnanam Umapathi2, Yukihiro Nishimoto3, Yu Zhong Wang4, Yee Cheun Chan5, Nobuhiro Yuki6.   

Abstract

Cerebrospinal fluid (CSF) protein level, cell count, and its relationship to the timing of lumbar puncture were collected from patients with Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS) from various Asian centers. A total of 507 patients with GBS were studied. Overall, 56% had elevated CSF protein level. This was significantly lower than that reported in a recent Dutch study (56% vs 64%). Cytoalbuminologic dissociation was also lower in the Asian cohort (55% vs 64%), with a significantly higher proportion of patients with mild pleocytosis (26% vs 15%). A lower proportion of the 164 patients with MFS had elevated CSF protein level (38% vs 56%), mild pleocytosis (11% vs 26%), and cytoalbuminologic dissociation (41% vs 55%) compared to patients with GBS. In both conditions, cytoalbuminologic dissociation was linked to the timing of lumbar puncture. Cytoalbuminologic dissociation was only observed in half of the Asian patients with GBS and MFS, and it is strongly dependent on the timing of the lumbar puncture.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  Guillain-Barré syndrome; Miller Fisher syndrome; cerebrospinal fluid; lumbar puncture

Mesh:

Substances:

Year:  2015        PMID: 25640907     DOI: 10.1111/jns.12104

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  10 in total

1.  Guillain-Barré Syndrome During the Postpartum Period.

Authors:  Mohammed Aabdi; Yassine Mellagui; Amine Bensaid; Houssam Bkiyar; Brahim Housni
Journal:  Cureus       Date:  2020-12-10

2.  Bulbar paralysis associated with Miller-Fisher syndrome and its overlaps in Chinese patients.

Authors:  Qiaoxia Hu; Hongfu Li; Jun Tian; Baorong Zhang
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

3.  Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.

Authors:  Pierre R Bourque; J Brooks; J Warman-Chardon; A Breiner
Journal:  J Neurol       Date:  2019-11-16       Impact factor: 4.849

4.  Clinical Reasoning: An 8-Year-Old With Acute Onset Ataxia.

Authors:  John Robert McLaren; Matthew Kyler Mitchell; Fatima Mohamed Al-Maadid; Kevin Joseph Staley
Journal:  Neurology       Date:  2022-06-03       Impact factor: 11.800

Review 5.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

6.  Age matters: Impact of data-driven CSF protein upper reference limits in Guillain-Barré syndrome.

Authors:  Pierre R Bourque; John Brooks; Christopher R McCudden; Jodi Warman-Chardon; Ari Breiner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-21

Review 7.  Diagnosis and management of Guillain-Barré syndrome in ten steps.

Authors:  Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2019-09-20       Impact factor: 42.937

8.  Case Report: Delayed Guillain-Barré syndrome following trauma: A case series and manage considerations.

Authors:  Yiliu Zhang; Chuxin Huang; Wei Lu; Qing Hu
Journal:  Front Surg       Date:  2022-08-25

9.  Guillain-Barré syndrome mimics.

Authors:  Sai Leong Tham; Kalpana Prasad; Thirugnanam Umapathi
Journal:  Brain Behav       Date:  2018-04-10       Impact factor: 2.708

10.  Cerebrospinal fluid analysis in Guillain-Barré syndrome: value of albumin quotients.

Authors:  Jakob Rath; Gudrun Zulehner; Bernadette Schober; Anna Grisold; Martin Krenn; Hakan Cetin; Fritz Zimprich
Journal:  J Neurol       Date:  2021-03-02       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.